Abstract
SCH 23390 [0.003-0.03 mg/kg, subcutaneously (SC)], a dopamine D 1 receptor antagonist, dose-dependently inhibited the ambulation-stimulant effect of methamphetamine (MAP) (2 mg/kg, SC) in mice when two drugs were combined in repeated administrations at 3- to 4-day intervals, repeated five times. SCH 23390 (0.03 mg/kg), which was sufficient to abolish the acute effect of MAP completely throughout the repeated administrations, significantly inhibited the induction of MAP sensitization. Moreover, when the mice were posttreated with SCH 23390 (0.01 and 0.03 mg/kg) 3 h after each MAP administration, at which the ambulation-stimulant effect of MAP had almost disappeared, they showed a significant and dose-dependent retardation of the induction of MAP sensitization. However, the 24-h posttreatment with SCH 23390 had no such effect. The administration of SCH 23390 (0.003–0.03 mg/kg) alone in either the activity cage or the home cage, or saline in the activity cage with 3- or 24-h posttreatment with SCH 23390 (0.01 or 0.03 mg/kg) five times at 3- to 4-day intervals did not elicit any significant changes in MAP sensitivity. The present results indicate that an intense blockade of dopamine D 1 receptors in the acute or subacute period after MAP administration causes retardation of MAP sensitization by means of ambulation in mice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.